Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors

Abstract The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and as a companion to both conventional a...

Full description

Bibliographic Details
Main Authors: Catherine T. Le, William J. Murphy
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-1
PD-L1
Exhaustion
Priming
T-cell
Preclinical modeling
Online Access:http://link.springer.com/article/10.1186/s40425-019-0789-4

Internet

http://link.springer.com/article/10.1186/s40425-019-0789-4

Similar Items